Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

c-Myb mRNA degrader REM-422

An orally bioavailable, small molecule mRNA degrader of the proto-oncogene c-Myb, with potential antineoplastic activity. Upon oral administration, c-Myb mRNA degrader REM-422 promotes the inclusion of poison exon into the c-Myb pre-mRNA transcript, resulting in the degradation of c-Myb mRNA and the reduction of both c-Myb mRNA and c-Myb protein levels. This may decrease proliferation in tumor cells with c-Myb dysregulation or overexpression. c-Myb, an oncogenic transcription factor that plays a key role in the regulation of hematopoietic cell differentiation and proliferation, is dysregulated or overexpressed in a variety of tumor cell types.
Synonym:c-Myb mRNA inhibitor REM-422
Myb mRNA degrader REM-422
Myb mRNA inhibitor REM-422
Code name:REM 422
REM-422
REM422
Search NCI's Drug Dictionary